Drug Insight: The mechanism of action of rituximab in autoimmune disease - The immune complex decoy hypothesis

Nature Clinical Practice Rheumatology

Volumn 3, Issue 2, 2007, Pages 86-95

  Taylor, Ronald P ^a   Lindorfer, Margaret A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G; RHESUS D ANTIBODY; RITUXIMAB;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG MECHANISM; DRUG PROTEIN BINDING; EFFECTOR CELL; HUMAN; IMMUNE COMPLEX DEPOSITION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIC PURPURA;

ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; RECEPTORS, IGG;

EID: 33847068351     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0424     Document Type: Review

References (64)

1. Grillo-Lopez A et al. (1999) Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26: 66-73
2. Edwards JCW et al. (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581
3. Gottenberg JE et al. (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64: 913-920
4. Eisenberg R and Abert D (2005) B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2: 1-6
5. Cohen SB et al. (2006) Rituximab for rheumatoid arthritis-refractory to anti-tumor necrosis factor therapy. Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthrifis Rheum 54: 2793-2806
6. Sfikakis PP et al. (2005) Rituximab anti-B-cell therapy in systemic lupus erythematosus: Pointing to the future. Curr Opin Rheumatol 17: 550-557
7. Edwards JCW and Cambridge G (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6: 394-403
8. Looney RJ (2006) B cell-targeted therapy for rheumatoid arthritis. An update on the evidence. Drugs 66: 625-639
9. Reff M E et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445
10. Kennedy AD et al. (2004) Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172: 3280-3288
11. Cragg MS et al. (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8: 140-174
12. Lefebvre M-L et al. (2006) Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 29: 388-397
13. Takai T (2005) Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 25: 1-18
14. Nimmerjahn F and Ravetch JV (2006) Fcγ receptors: Old friends and new family members. Immunity 24: 19-28
15. Nimmejahn F and Ravetch JV (2005) Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310: 1510-1512
16. Wang WK and Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 3940-3947
17. Cartron G et al. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99: 754-758
18. Anolik JH et al. (2003) The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48: 455-459
19. Edwards JCW and Cambridge G (1998) Rheumatoid arthritis: The predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol 37: 126-130
20. Nimmerjahn F et al. (2005) FcγRIV: A novel FcR with distinct IgG subclass specificity. Immunity 23: 41-51
21. Shushakova N et al. (2002) C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex-induced lung disease. J Clin Invest 110: 1823-1830
22. Schmidt RE and Gessner JE (2005) Fc receptors and their interaction with complement in autoimmunity. Immunol Lett 100: 56-67
23. Kumar V et al. (2006) Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 116: 512-520
24. Huber-Lang M et al. (2006) Generation of C5a in the absence of C3: A new complement activation pathway. Nat Med 12: 682-687
25. Badger AM (2000) Antimacrophage therapies. In Rheumatoid arthritis: frontiers in pathogenesis and treatment, 539-549 (Eds Firestein GS et al.) New York: Oxford University Press
26. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423: 356-361
27. van Roon JAG et al. (2003) Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcγ receptor I-directed immunotoxin. Arthritis Rheum 48: 1229-1238
28. Wijngaarden S et al. (2004) A shift in the balance of inhibitory and activating Fcγ receptors on monocytes toward the inhibitory Fcγ receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum 50: 3878-3887
29. Samuelsson A et al. (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486
30. Clynes R et al. (1998) Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279: 1052-1054
31. Marino M et al. (2000) Prevention of systemic lupus erythematosus in MRL/ Ipr mice by administration of an immunoglobulin-binding pepticle. Nature Biotechnol 18: 735-739
32. Frank MM et al. (1979) Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 300: 518-523
33. Salmon JE (2000) Abnormalities in immune complex clearance and Fcγ receptor function. In Dubois' Lupus Erythematosus, 219-242 (Eds Wallace DJ and Hahn BH) Baltimore: Williams and Wilkins
34. Manderson AP et al. (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22: 431-456
35. Zvaifler NJ (1973) The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol 16: 265-336
36. Ji H et al. (2002) Arthritis critically dependent on innate immune system players. Immunity 16: 157-168
37. Bruhns P et al. (2003) Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18: 573-581
38. Kaplan CD et al. (2005) Development of proteoglycan-induced arthritis is critically dependent on Fcγ receptor III expression. Arthritis Rheum 52: 1612-1619
39. O'Neill SK et al. (2005) Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol 174: 3781-3788
40. Anolik JH et al. (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50: 3580-3590
41. Eisenberg R and Looney RJ (2005) The therapeutic potential of anti-CD20: what do B-cells do? Clin Immunol 17: 207-213
42. Sfikakis PP et al. (2005) Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand. Arthritis Rheum 52: 501-513
43. Leandro MJ et al. (2005) B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology (Oxford) 44: 1542-1545
44. Swaak AJG et al. (1986) Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45: 359-366
45. Looney RJ et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580-2589
46. McLaughlin P (2001) Rituximab: Perspective on single agent experience, and future directions in combination trials. Crit Rev Oncol Hematol 40: 3-16
47. Taylor RP et al. (1981) Studies of artificial cryoprecipitates containing anti-DNA antibody activity. Rheumatol Int 1: 1-6
48. Bussel JB et al. (1991) Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect. Blood 77: 1884-1893
49. Scaradavou A et al. (1997) Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients. Blood 89: 2689-2700
50. Stasi R et al. (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98: 952-957
51. Zaja F et al. (2003) The B-cell compartment as the selective target for the treatment of immune thrombacytopenias. Haematologica 88: 538-546
52. Song S et al. (2003) Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: An alternative to IVIG. Blood 101: 3708-3713
53. Siragam V et al. (2005) Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 115: 155-160
54. Song S et al. (2005) Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 105: 1546-1548
55. Bowles JA and Weiner GJ (2005) CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Meth 304: 88-99
56. Schroder C et al. (2003) Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transplant Immunol 12: 19-28
57. Vugmeyster Y et al. (2003) Differential in vivo effects of rituximab on two B-call subsets in cynomolgus monkeys. Int Immunopharmacol 3: 1477-1481
58. Vugmeyster Y et al. (2005) Depletion of B cells by a humanized anti-CD20 antibody PR070769 in Macaca fascicularis. J Immunother 28: 212-219
59. + cells by rituximab. Blood 101: 1071-1079
60. Uwatoko S et al. (1995) C1 q-binding immunoglobulin in MRL/I mice consists of immune complexes containing antibodies to DNA. Clin Immunol Immunopath 75: 140-146
61. Hamaguchi Y et al. (2005) The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 174: 4389-4399
62. Gong Q et al. (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174: 817-826
63. Cardarelli PM et al. (2002) Binding to CD20 by anti-B1 antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 51: 15-24
64. Ravetch JV (2003) Fc receptors. In Fundamental Immunology, 685-700 (Ed Paul WE) Philadelphia: Lippincott Williams & Wilkins